Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma

被引：2

作者：

Dichmann, S

Mrowietz, U

Schöpf, E

Norgauer, J

机构：

[1] Univ Freiburg, Hautklin, Dept Dermatol, D-79104 Freiburg, Germany

[2] Univ Kiel, Dept Dermatol, D-24098 Kiel, Germany

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2002年 / 47卷 / 04期

关键词：

D O I：

10.1067/mjd.2002.122751

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：635 / 636

页数：2

共 4 条

[1] Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis [J].

Krueger, JG ;

Walters, IB ;

Miyazawa, M ;

Gilleaudeau, P ;

Hakimi, J ;

Light, S ;

Sherr, A ;

Gottlieb, AB .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (03) :448-458

[2] Treatment of severe psoriasis with anti-CD25 monoclonal antibodies [J].

Mrowietz, U ;

Zhu, KJ ;

Christophers, E .

ARCHIVES OF DERMATOLOGY, 2000, 136 (05) :675-676

[3] Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker) [J].

Salim, A ;

Emerson, RM ;

Dalziel, KL .

BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (05) :1121-1122

[4] Treatment of recalcitrant psoriasis with daclizumab [J].

Wohlrab, J ;

Fischer, M ;

Taube, KM ;

Marsch, WC .

BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (01) :209-210

← 1 →